4[3]Bernhard H L Bhm,Rainer H Müller,Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs[J].Drug Deliv Rev,1999,2:336-339.
5[5]Mehnert.W,Mader.K.Solid lipid nanoparticles production,characterization and applications[J].Adv Drug Deliv Rev,2001,47:165-196.
6[6]Rainer H.Müller,Karsten Mader.Solid lipid nanoparticles(SLN) for controlled drug delivery - a review of the state of the art[J].European Journal of Pharmaceutics and Biopharmaceutics,2000,50:161-177.
7MEHNERT W, MADER K. Solid lipid nanoparticles production, characterization and applications [J].Adv Drug Deliv Rev,2001, 47(2-3):165-196.
8MULLER R H,MADER K,GOHLA S.Solid lipid nanoparticles(SLN) for controlled drug delivery: a review of the state of the art [J].Eur J Pharm biopharm,2000,50(1):161-177.
9ARAIZ J J,REFOJO M F,ARROYO M H,et al.Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy [J].Invest Ophthalmol Vis Sci,1993,34:522-530.
